Patents by Inventor Miles Andrew Nunn

Miles Andrew Nunn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Coversin (OmCI) for the treatment of autoimmune blistering diseases: bullous pemphigoid (BP) and epidermolysis bullosa acquisita (EBA)
    Patent number: 11730792
    Abstract: The present invention relates to methods of treating or preventing AIBD.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: August 22, 2023
    Assignee: Volution Immuno Pharmaceuticals SA
    Inventors: Miles Andrew Nunn, Brihad Abhyankar, Christian David Sadik
  • Coversin Variants Lacking C5 Binding
    Publication number: 20230002456
    Abstract: The invention is directed to modified Coversin polypeptides which exhibit leukotriene or hydroxyeicosanoid binding activity and reduced or absent C5 binding relative to the unmodified Coversin polypeptide; to nucleic acid molecules encoding said modified Coversin polypeptides; vectors and host cells comprising said nucleic acid molecules; and methods of treating or preventing diseases or conditions mediated by a leukotriene or hydroxyeicosanoid in a subject comprising administering said modified polypeptides or nucleic acids to a subject.
    Type: Application
    Filed: November 18, 2021
    Publication date: January 5, 2023
    Applicant: Volution Immuno Pharmaceuticals SA
    Inventor: Miles Andrew Nunn
  • Method of Inhibiting C5 Cleavage
    Publication number: 20220363726
    Abstract: The invention relates to complement inhibitors that inhibit both the classical and alternative complement pathways. In particular, the invention relates to complement inhibitors derived from the salivary glands of haematophagous arthropods that inhibit both the classical and alternative complement pathways. The invention also relates to the use of the complement inhibitors in the treatment and prevention of diseases.
    Type: Application
    Filed: January 5, 2022
    Publication date: November 17, 2022
    Applicant: VOLUTION IMMUNO PHARMACEUTICALS SA
    Inventor: Miles Andrew Nunn
  • Coversin variants lacking C5 binding
    Patent number: 11214602
    Abstract: The invention is directed to modified Coversin polypeptides which exhibit leukotriene or hydroxyeicosanoid binding activity and reduced or absent C5 binding relative to the unmodified Coversin polypeptide; to nucleic acid molecules encoding said modified Coversin polypeptides; vectors and host cells comprising said nucleic acid molecules; and methods of treating or preventing diseases or conditions mediated by a leukotriene or hydroxyeicosanoid in a subject comprising administering said modified polypeptides or nucleic acids to a subject.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: January 4, 2022
    Assignee: Volution Immuno Pharmaceuticals, SA
    Inventor: Miles Andrew Nunn
  • Methods For Treatment of Neuropathic Pain
    Publication number: 20210171588
    Abstract: Methods of treating neuropathic pain are provided. In particular, the invention provides a method for treating neuropathic pain related mechanical hypersensitivity (allodynia and hyperalgesia) and peripheral neuropathic pain.
    Type: Application
    Filed: December 7, 2018
    Publication date: June 10, 2021
    Applicant: Volution Immuno Pharmaceuticals SA
    Inventors: Paul Louis Chazot, Miles Andrew Nunn, Ilona Genowefa Obara
  • COVERSIN VARIANTS LACKING C5 BINDING
    Publication number: 20200385434
    Abstract: The invention is directed to modified Coversin polypeptides which exhibit leukotriene or hydroxyeicosanoid binding activity and reduced or absent C5 binding relative to the unmodified Coversin polypeptide; to nucleic acid molecules encoding said modified Coversin polypeptides; vectors and host cells comprising said nucleic acid molecules; and methods of treating or preventing diseases or conditions mediated by a leukotriene or hydroxyeicosanoid in a subject comprising administering said modified polypeptides or nucleic acids to a subject.
    Type: Application
    Filed: April 20, 2018
    Publication date: December 10, 2020
    Applicant: VOLUTION IMMUNO PHARMACEUTICALS SA
    Inventor: Miles Andrew Nunn
  • COVERSIN FOR THE TREATMENT OF AUTOIMMUNE BLISTERING DISEASES
    Publication number: 20200113971
    Abstract: The present invention relates to methods of treating or preventing AIBD.
    Type: Application
    Filed: April 20, 2018
    Publication date: April 16, 2020
    Applicant: VOLUTION IMMUNO PHARMACEUTICALS SA
    Inventors: Miles Andrew Nunn, Brihad Abhyankar, Christian David Sadik
  • METHOD OF INHIBITING C5 CLEAVAGE
    Publication number: 20180127472
    Abstract: The invention relates to complement inhibitors that inhibit both the classical and alternative complement pathways. In particular, the invention relates to complement inhibitors derived from the salivary glands of haematophagous arthropods that inhibit both the classical and alternative complement pathways. The invention also relates to the use of the complement inhibitors in the treatment and prevention of diseases.
    Type: Application
    Filed: August 17, 2017
    Publication date: May 10, 2018
    Applicant: VOLUTION IMMUNO PHARMACEUTICALS SA
    Inventor: Miles Andrew Nunn
  • Method of inhibiting C5 cleavage
    Patent number: 9834585
    Abstract: The invention relates to complement inhibitors that inhibit both the classical and alternative complement pathways. In particular, the invention relates to complement inhibitors derived from the salivary glands of haematophagous arthropods that inhibit both the classical and alternative complement pathways. The invention also relates to the use of the complement inhibitors in the treatment and prevention of diseases.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: December 5, 2017
    Assignee: Volution Immuni Pharmaceuticals SA
    Inventor: Miles Andrew Nunn
  • COMPLEMENT INHIBITORS
    Publication number: 20160096870
    Abstract: The invention relates to complement inhibitors that inhibit both the classical and alternative complement pathways. In particular, the invention relates to complement inhibitors derived from the salivary glands of haematophagous arthropods that inhibit both the classical and alternative complement pathways. The invention also relates to the use of such complement inhibitors in the treatment and prevention of diseases.
    Type: Application
    Filed: February 18, 2015
    Publication date: April 7, 2016
    Inventor: Miles Andrew NUNN
  • Complement inhibitors
    Patent number: 8993264
    Abstract: The invention relates to complement inhibitors that inhibit both the classical and alternative complement pathways. In particular, the invention relates to complement inhibitors derived from the salivary glands of haematophagous arthropods that inhibit both the classical and alternative complement pathways. The invention also relates to the use of such complement inhibitors in the treatment and prevention of diseases.
    Type: Grant
    Filed: February 7, 2011
    Date of Patent: March 31, 2015
    Assignee: Volution Immuno Pharmaceuticals SA
    Inventor: Miles Andrew Nunn
  • Complement inhibitors
    Publication number: 20110263482
    Abstract: The invention relates to complement inhibitors that inhibit both the classical and alternative complement pathways. In particular, the invention relates to complement inhibitors derived from the salivary glands of haematophagous arthropods that inhibit both the classical and alternative complement pathways. The invention also relates to the use of such complement inhibitors in the treatment and prevention of diseases.
    Type: Application
    Filed: February 7, 2011
    Publication date: October 27, 2011
    Inventor: Miles Andrew Nunn
  • Detection of amplicon contamination during PCR exhibiting two different annealing temperatures
    Patent number: 7914986
    Abstract: A method to perform PCR reactions with one set of primers comprising sequence elements that are complementary to the target sequence and comprising sequence elements that server as tagging sequences. By conducting amplification reactions at different temperatures, the presence of contaminations arising from amplification products of previous reactions can be determined, improving reliability of the reaction and reducing the need for control reactions and reproduction of reactions.
    Type: Grant
    Filed: May 19, 2005
    Date of Patent: March 29, 2011
    Assignee: Amplion Limited
    Inventor: Miles Andrew Nunn
  • Complement inhibitors
    Patent number: 7884188
    Abstract: The invention relates to complement inhibitors that inhibit both the classical and alternative complement pathways. In particular, the invention relates to complement inhibitors derived from the salivary glands of haematophagous arthropods that inhibit both the classical and alternative complement pathways. The invention also relates to the use of such complement inhibitors in the treatment and prevention of diseases.
    Type: Grant
    Filed: June 2, 2004
    Date of Patent: February 8, 2011
    Assignee: Varleigh Immuno Pharmaceuticals (VIP) Ltd
    Inventor: Miles Andrew Nunn
  • Detection of amplicon contamination during pcr exhibiting two different annealing temperatures
    Publication number: 20090311672
    Abstract: A method to perform PCR reactions with one set of primers comprising sequence elements that are complementary to the target sequence and comprising sequence elements that server as tagging sequences. By conducting amplification reactions at different temperatures, the presence of contaminations arising from amplification products of previous reactions can be determined, improving reliability of the reaction and reducing the need for control reactions and reproduction of reactions.
    Type: Application
    Filed: May 19, 2005
    Publication date: December 17, 2009
    Inventor: Miles Andrew Nunn